Difficulty: Medium
Average Score: 84%
Practice
Polymorphic ventricular tachycardia can occur when terfenadine
Correct answer
B
Rationale
In this scenario, the correct answer is B) Is coadministered with fluconazole.
Terfenadine is a non-sedating antihistamine that was withdrawn from the market due to its potential to cause fatal arrhythmias by prolonging the QT interval. Fluconazole is an antifungal medication that inhibits the metabolism of terfenadine, leading to increased levels of terfenadine in the body. This increased concentration can further prolong the QT interval, predisposing the individual to polymorphic ventricular tachycardia like Torsades de Pointes.
Option A) Is coadministered with azithromycin is incorrect because azithromycin does not have a significant interaction with terfenadine.
Option C) Is given in higher doses is incorrect because the risk of polymorphic ventricular tachycardia is related to drug interactions and not just higher doses of terfenadine alone.
Option D) Reduces QT interval is incorrect because terfenadine actually prolongs the QT interval, which is why it can lead to serious cardiac arrhythmias.
This question highlights the importance of understanding drug interactions, particularly those that can impact cardiac electrophysiology. Healthcare providers need to be aware of potential drug interactions that can lead to QT prolongation and associated arrhythmias to ensure patient safety when prescribing medications that affect the cardiovascular system.
Terfenadine is a non-sedating antihistamine that was withdrawn from the market due to its potential to cause fatal arrhythmias by prolonging the QT interval. Fluconazole is an antifungal medication that inhibits the metabolism of terfenadine, leading to increased levels of terfenadine in the body. This increased concentration can further prolong the QT interval, predisposing the individual to polymorphic ventricular tachycardia like Torsades de Pointes.
Option A) Is coadministered with azithromycin is incorrect because azithromycin does not have a significant interaction with terfenadine.
Option C) Is given in higher doses is incorrect because the risk of polymorphic ventricular tachycardia is related to drug interactions and not just higher doses of terfenadine alone.
Option D) Reduces QT interval is incorrect because terfenadine actually prolongs the QT interval, which is why it can lead to serious cardiac arrhythmias.
This question highlights the importance of understanding drug interactions, particularly those that can impact cardiac electrophysiology. Healthcare providers need to be aware of potential drug interactions that can lead to QT prolongation and associated arrhythmias to ensure patient safety when prescribing medications that affect the cardiovascular system.